Relapse Rate Reduction: Ocrelizumab vs Natalizumab
The claim that ocrelizumab achieves 90% relapse reduction while natalizumab achieves 80% is not accurate based on FDA-approved data—both medications demonstrate similar relapse rate reductions of approximately 46-47% compared to interferon beta-1a, not 80-90% as absolute reductions.
Understanding the Numbers
The confusion likely stems from misinterpreting relative versus absolute reductions. Here's what the highest-quality evidence actually shows:
Ocrelizumab (Ocrevus) - FDA Label Data
In the pivotal RMS trials 1:
- Annualized relapse rate (ARR): 0.156 (Study 1) and 0.155 (Study 2)
- Relative reduction vs interferon beta-1a: 46-47% (p<0.0001)
- Proportion relapse-free at 96 weeks: 82-83%
The "90%" figure you may have seen likely refers to the 94-95% reduction in MRI gadolinium-enhancing lesions 1, not clinical relapses.
Natalizumab (Tysabri) - Real-World Data
Recent high-quality real-world evidence shows 2:
- Mean ARR on treatment: 0.04 (compared to 0.69 pre-treatment)
- ARR reduction: Approximately 82-94% from baseline
- Proportion with relapses: Only 8.4% during treatment (vs 88.5% pre-treatment)
- NEDA-3 achievement: 84.0%
Another Swiss cohort demonstrated 3:
- ARR reduction: 82% at 1 year, 69% at 2 years, 77% at 3 years (all p<0.001)
Head-to-Head Comparison
The most recent and highest-quality direct comparison found no significant difference between these medications 4:
A 2026 Danish nationwide registry study comparing ocrelizumab (n=542) versus natalizumab (n=384) in RRMS patients found:
- Mean ARR: 0.071 for both groups (95% CI overlap completely)
- ARR ratio: 0.996 (95% CI 0.687-1.444, p=0.983)
- No difference in disability progression or MRI activity
However, one 2026 US claims-based study suggested natalizumab may have slightly better outcomes 5:
- ARR: 0.20 (natalizumab) vs 0.28 (ocrelizumab), rate ratio 0.70 (p<0.001)
- Relapse-free at 3 years: 69.9% vs 63.9% (p=0.002)
Clinical Bottom Line
Both medications are highly effective high-efficacy DMTs with:
- Similar relapse suppression in the 80-90% relapse-free range
- Comparable disability outcomes
- Excellent MRI activity control
Key Differentiating Factors
Choose natalizumab when:
- JCV antibody negative or low index (<1.5)
- Desire for rapid onset of action
- Preference for monthly monitoring
Choose ocrelizumab when:
- JCV antibody positive with high index (>1.5)
- Preference for less frequent dosing (every 6 months)
- Primary progressive MS (only approved option)
Critical Safety Caveat
Natalizumab carries significant PML risk 6:
- Overall PML incidence: 3.96 per 1000 patients
- Risk stratified by JCV antibody status, prior immunosuppression, and treatment duration
- After 25-48 months in JCV+ patients: 5/1000 (no prior immunosuppression) to 11/1000 (with prior immunosuppression)
- With JCV index >1.5 after 49-72 months: 10.12/1000
Ocrelizumab does not carry this specific PML risk profile, making it safer for long-term use in JCV-positive patients.